

Policy: MP187

Section: Medical Benefit Policy

Subject: Cryoablation

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Cryoablation

II. Purpose/Objective:

To provide a policy of coverage regarding Cryoablation

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.

- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION: Cryosurgery or cryoablation is a technique involving the use of extremely low temperatures to destroy tumors that are left in place to be reabsorbed. It is a focal therapy that allows treatment of specific lesions with preservation of normal tissue.

INDICATIONS: The following indications have been evaluated by the Geisinger Technology Assessment Committee and are considered to be medically necessary.

- I. *Cryoablation* for the treatment of hepatic tumors may be considered medically necessary for patients with unresectable primary liver cancer or unresectable metastatic liver tumors with no evidence of extrahepatic disease.
- II. *Cryoablation* for the treatment of Prostate Cancer may be considered medically necessary if **ANY** of the following criteria are met:
 1. Member with T1 prostate cancer; **or**
 2. Member with T2 prostate cancer; **or**
 3. Member with T3 prostate cancer when regional lymph nodes have been evaluated and determined to be cancer free; **or**
 4. As a salvage therapy for recurrent prostate cancer following failure of radiation therapies when the member has a prostate-specific antigen (PSA) of less than 8ng/mL, a Gleason score less than 9, or a disease state of T2B or below.

Primary Tumor Stages

Tx	Primary tumor cannot be assessed	T2b	Tumor involves more than half a lobe but not both lobes
T0	No evidence of primary tumor	T3	Tumor extends through the prostatic capsule
T1	Clinically inapparent tumor not palpable or visible by imaging	T3a	Unilateral extracapsular extension
T1a	Tumor incidental histologic finding in <5% of tissue resected via transurethral resection (TURP)	T3b	Bilateral extracapsular extension
T1b	Tumor incidental histologic finding in >5% of tissue resected via (TURP)	T3c	Tumor invades the seminal vesicle(s)
T1c	Tumor identified by needle biopsy	T4	Tumor is fixed or invades adjacent structures other than the seminal vesicles
T2	Tumor palpable but confined within the prostate	T4a	Tumor invades any of the bladder neck, external sphincter or rectum
T2a	Tumor involves half a lobe or less	T4b	Tumor invades levator muscles and/or is fixed to the pelvic wall
T2b	Tumor involves more than half a lobe but not both lobes		

From: The Prostate Cancer Research Institute (PCRI)

- III. *Cryoablation* for the treatment of renal tumors may be considered medically necessary when **ALL** of the following criteria are met:
 1. Member has a solitary kidney or in need of nephron-sparing procedure to preserve renal function; **AND**
 2. Tumor is less than 4 cm in size; **AND**
 3. Member presents with concomitant co-morbidities which increase the risk of renal insufficiency (i.e. Diabetes, Morbid Obesity, etc.)

*Note; Renal insufficiency is defined as glomerular filtration rate is less than or equal to 60/ml/min/m²

- IV. *Cryoablation* for the treatment of low-risk superficial basal cell carcinoma, and squamous cell carcinoma in situ (Bowen disease), may be considered medically necessary when surgery or radiation is contraindicated or impractical.

- V. Cryoablation for the treatment of soft tissue sarcoma of the extremities may be considered medically necessary in symptomatic members with disseminated metastases.
- VI. Cryoablation for the treatment of malignant endobronchial obstruction is considered medically necessary
- VII. Cryoablation may be considered medically necessary to treat lung cancer when either of the following criteria is met:
The member has early-stage non-small cell lung cancer and is a poor surgical candidate;
or
The member requires palliation for a central airway obstructing lesion.
- VIII. Cryoablation for the treatment of atrial fibrillation in association with other cardiac surgery may be considered medically necessary.
- IX. Cryoablation for the treatment of cervical intraepithelial neoplasia is considered medically necessary.
- X. Cryoablation for the treatment of colon cancer with oligometastases to the lungs and/or liver is considered medically necessary
- XI. Cryoablation in the treatment of Grade I intracompartmental bone cancer as an adjuvant to intralesional curettage is considered medically necessary
- XII. Cryoablation for the treatment of knee pain secondary to osteoarthritis is considered medically necessary. **(Please see MP329 Genicular Nerve Ablation)**
- XIII. Cryoablation for the treatment of nerve pain is considered medically necessary.

EXCLUSIONS:

Cryoablation of benign or malignant breast lesions because it is considered **experimental, investigational or unproven** and therefore **NOT COVERED**. The Geisinger Technology Assessment Committee evaluated this technology and concluded that there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established tests or technologies.

For the Medicaid Business Segment cryoablation of breast fibroadenoma may be considered as a program exception.

Cryoablation for the treatment of plantar fasciitis or plantar fibroma because it is considered **experimental, investigational or unproven** and therefore **NOT COVERED**. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established tests or technologies.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in **MP 15 - Experimental Investigational or Unproven Services or Treatment**.

CODING ASSOCIATED with: Cryoablation

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services.

- 19105 Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma
- 20983 ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation
- 31641 Bronchoscopy (rigid or flexible); with destruction of tumor or relief of stenosis by any

- method other than excision (e.g., laser therapy, cryotherapy)
- 33257 Operative tissue ablation and reconstruction of atria, performed at the time of other cardiac procedure(s), limited (eg, modified maze procedure) (List separately in addition to code for primary procedure)
- 32994 Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation
- 47371 Laparoscopy, surgical, ablation of one or more liver tumor(s); cryosurgical
- 47381 Ablation, open, of one or more liver tumor(s); cryosurgical
- 47383 ablation, 1 or more liver tumor(s), percutaneous, cryoablation
- 50250 Ablation, open, one or more renal mass lesions(s), cryosurgical, including intraoperative ultrasound, if performed.
- 50542 Laparoscopy, surgical; ablation of renal mass lesion(s)
- 50593 Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy
- 55873 Cryosurgical ablation of the prostate (includes ultrasonic guidance for interstitial cryosurgical probe placement)
- 57511 Cautery of cervix; cryocautery, initial or repeat
- 76942 Ultrasonic guidance for needle placement (e.g. biopsy, aspiration, injection, localization device), imaging supervision and interpretation.
- 76940 Ultrasound guidance for, and monitoring of, visceral tissue ablation.
- 0440T Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve
- 0441T Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve
- 0442T Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)
- 0581T ABLATION, MALIGNANT BREAST TUMOR(S), PERCUTANEOUS, CRYOTHERAPY, INCLUDING IMAGING GUIDANCE WHEN PERFORMED, UNILATERAL

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

"Renal Cryoablation", Geisinger Technology Assessment Committee, July 12, 2006.

"Breast Cryoablation", Geisinger Technology Assessment Committee, July 12, 2006.

Geisinger TAC Triage Committee. Cryoablation. February 2006.

Kauffman CS, Bachman B, et al. Cryoablation treatment of benign breast lesions with 12-month follow-up. Am J Surg. 2004 Oct;188(4):340-8.

Hartmann LC, Sellers TA, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21;353(3):229-37.

American Society of Breast Surgeons. Management of Fibroadenomas of the Breast. September 2004.

Sanarus Medical Inc. [Website] Medical professionals page. Visica Treatment System. 2002 Available at <http://www.sanarus.com/medpro/visica.html>

Singletary SE. Minimally invasive techniques in breast cancer treatment. Semin Surg Oncol. 2001;20:246-250.

Huston TL, Simmons RM. Ablative therapies for the treatment of malignant diseases of the breast. Am J Surg. 2005 Jun;189(6):694-701.

Edwards MJ, Broadwater R, et al. Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice. Am J Surg. 2004 Sep;188(3):221-4.

Nurko J, Mabry CD, et al. Interim results from the FibroAdenoma Cryoablation Treatment Registry. Am J Surg. 2005 Oct;190(4):647-51; discussion 651-2.

Whitworth PW, Rewcastle JC. Cryoablation and cryolocalization in the management of breast disease. *J Surg Oncol*. 2005 Apr 1;90(1):1-9.

Littrup PJ, Freeman-Gibb L., et al. Cryotherapy for breast fibroadenomas. *Radiology*. 2005 Jan;234(1):63-72.

Kauffman CS, Littrup PJ, et al. Office-based cryoablation of breast fibroadenomas with long-term follow-up. *Breast J*. 2005 Sep-Oct;11(5):344-50.

Winifred S. Hayes Inc. Online medical directory: Cryoablation for Treatment of Breast Fibroadenomas. Online June 10, 2002. Updated May 25, 2005.

ECRI. Cryosurgery for Breast Cancer and Breast Fibroadenoma [HTAIS Hotline Response]. April 29, 2005

Pfleiderer SO, Freesmeyer MG, et al. Cryotherapy of breast cancer under ultrasound guidance: initial results and limitations. *Eur Radiol*. 2002 Dec;12(12):3009-14.

Tafra L, Smith SJ, et al. Pilot trial of cryoprobe-assisted breast-conserving surgery for small ultrasound-visible cancers. *Ann Surg Oncol*. 2003 Nov;10(9):1018-24.

Sabel MS, Kauffman CS, et al. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. *Ann Surg Oncol*. 2004 May;11(5):542-9.

Morin T, Traore A, et al. Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results. *Can J Surg*. 2004 Oct;47(5):347-51.

Sotsky TK, Ravikumar TS. Cryotherapy in the treatment of liver metastases from colorectal cancer. *Semin Oncol*. 2002 Apr;29(2):183-91.

Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. *Ann Surg*. 1998 Aug;228(2):201-8.

Bilchik AJ, Wood TF, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. *Arch Surg*. 2000 Jun;135(6):657-62

Dodd GD, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. *Radiographics*. 2000;20(1):9-27

Goering JD, Mahvi DM, et al. Cryoablation and liver resection for noncolorectal liver metastases. *Am J Surg*. 2002 Apr;183(4):384-9.

Winifred S. Hayes Inc. Online medical directory: Cryosurgery for primary and Metastatic Liver Tumors. Online October 22, 2004.

Jungraithmav W, Burger D, et al. Cryoablation of malignant liver tumors: results of a single center study. *Hepatobiliary Pancreat Dis Int*. 2005 Nov;4(4):554-60.

HGSA Local Coverage Determination. Cryosurgical Ablation of Hepatic Tumors (S-137B). Accessed on November 17, 2005 at <http://www.hgsa.com/professionals/lcd/s137b.html>

Kerkar S, Carlin AM, et al. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. *Surgery*. 2004 Oct;136(4):770-9.

Seifert JK, Springer A, et al. Liver resection or cryotherapy for colorectal liver metastases A prospective case control study. *Int J Colorectal Dis*. 2005 Nov;20(6):507-20.

Khatri VP, McGahan J. Non-resection approaches for colorectal liver metastases. *Surg Clin North Am*. 2004 Apr;84(2):587-606.

Sheen AJ, Siriwardena AK. The end of cryotherapy for the treatment of nonresectable hepatic tumors? *Ann Surg Oncol*. 2005 Mar;12(3):202-4.

Lau YW, Leung TW, et al. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. *Ann Surg.* 2003 Feb;237(2):171-9.

Khorsandi M, Foy RC, Chong W, Hoenig DM, Cohen JK, Rukstalis DB. Preliminary experience with cryoablation of renal lesions smaller than 4 centimeters. *JAOA* May 2002;102(5):277-281.

Lee DI, McGinnis DE, et al. Retroperitoneal laparoscopic cryoablation of small renal tumors: intermediate results. *Urology.* 2003 Jan;61(1):83-8.

Rukstalis DB, Khorsandi M, et al. Clinical experience with open renal cryoablation. *Urology.* 2001 Jan;57(1):34-9.

Nader RB, Kim SC, et al. Laparoscopic renal cryosurgery: the Northwestern experience. *J Urol.* 2003 Oct;170(4 Pt 1):1121-5.

Gill IS, Remer EM, et al. Renal cryoablation: outcome at 3 years. *J Urol.* 2005 Jun;173(6):1903-7.

Cestari A, Guazzoni G, et al. Laparoscopic cryoablation of solid renal masses: intermediate term followup. *J Urol.* 2004 Oct;172(4 Pt 1):1267-70.

Johnson DB, Solomon SB, et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. *J Urol.* 2004 Sep;172(3):874-7.

Desai MM, Aron M, et al. Laparoscopic partial nephrectomy versus laparoscopic cryoablation for the small renal tumor. *Urology.* 2005 Nov;66(5 Suppl):23-8.

Silverman SG, Tuncali K , et al. Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients. *Radiology.* 2005 Aug;236(2):716-24.

Winifred S. Hayes Inc. Alert-Technology Assessment Brief: Cryosurgery for Renal Masses. Online Volume VII, Number 3 - March 2004.

American Cancer Society (ACS) [website]. What's New in Kidney Cancer (Renal Cell Carcinoma) Research and Treatment? Revised November 21,2005. Accessed on November 28, 2005 at:

Chin JL, Touma N, et al. Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. *J Urol.* 2003 Oct;170(4 Pt 1):1199-202.

Han KR, Cohen JK, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. *J Urol.* 2003 Oct;170(4 Pt 1):1126-30.

Donnelly BJ, Saliken JC, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. *Urology.* 2002 Oct;60(4):645-9.

Centers for Medicare and Medicaid Services, CMS Coverage Issues Manual 35-96 Cryosurgery of Prostate. Accessed on November 17, 2005 at http://www.cms.hhs.gov/manuals/06_cim/ci35.asp

Prepelica KL., Okeke Z, et al. Cryosurgical ablation of the prostate: high risk patient outcomes. *Cancer.* 2005 Apr 15;103(8):1625-30.

Schmidt JD, Doyle J, Larison S. Prostate Cryoablation: update 1998. *Ca Cancer J Clin.* 1998.

American Urological Association. Cryoablation for prostate cancer. 2004 May Accessed on January 5, 2006 at: <http://www.urologyhealth.org/adult/index.cfm?cat=04&topic=42&x=18&y=12>

American Urological Association. Statement on salvage cryosurgical ablation of the prostate 2000 November. Accessed on November 28, 2005 at:

National Institute for Clinical Excellence (NICE). Interventional procedures overview of salvage cryotherapy for recurrent prostate cancer. Interventional Procedures Programme. NICE London UK. 2004 Available at <http://www.nice.org.uk>

Bahn DK, Lee F, et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. *Urology*. 2002 Aug;60(2 Suppl 1):3-11.

Winifred S. Hayes Inc. Online medical directory: Cryoablation for Prostate Cancer. Online October 16, 2001. Updated on October 2, 2005.

ECRI. Cryosurgery for prostate cancer. Target Database. Plymouth Meeting (PA): ECRI: Updated May 1999

Mack CA, Milla F, Ko W, Girardi LN, Lee LY, Tortolani AJ, Mascitelli J, Krieger KH, Isom OW. Surgical treatment of atrial fibrillation using argon-based cryoablation during concomitant cardiac procedures. *Circulation*. 2005 Aug 30; 112(9 Suppl):11-6.

Drago F, De Santis A, Grutter G, Silvetti MS. Transvenous cryothermal catheter ablation of re-entry circuit located near atrioventricular junction in pediatric patients. *J Am Coll Cardiol* 2005;45:1096-103.

Asimakopoulos G, et al. Cryosurgery for malignant endobronchial tumors: analysis of outcome. *Chest* 2005 June;127(6):2007-2014.

Kovach SJ, Hendrickson RJ, et al. Cryoablation of unresectable pancreatic cancer. *Surgery*. 2002 Apr;131(4):463-4.

Johnson MH, Eastone JA, et al. Cryoablation of Barrett's esophagus: a pilot study. *Gastrointest Endosc*. 2005 Dec;62(6):842-8.

Malawer MM, Dunham W. Cryosurgery and acrylic cementation as surgical adjuncts in the treatment of aggressive (benign) bone tumors. Analysis of 25 patients below the age of 21. *Clin Orthop Relat Res*. 1991 Jan;(262):42-57.

Allen BH, Fallat LM, Schwartz SM. Cryosurgery: an innovative technique for the treatment of plantar fasciitis. *J Foot Ankle Surg*. 2007 Mar-Apr;46(2):75-9.

National Comprehensive Cancer Network (NCCN). Basal and squamous cell skin cancers. NCCN Clinical Practice Guidelines in Oncology v.1.2009. Fort Washington, PA: NCCN; 2009

The Prostate Cancer Research Institute (PCRI) The Clinical Stage: Its Definition and Importance in Prostate Cancer. April 2000 v3.1 accessed on 10/4/11 http://www.prostatecancer.org/education/staging/Pinchof_Clinical_Stage.html

National Institute for Health and Clinical Excellence (NICE). Cryotherapy for malignant endobronchial obstruction. Interventional Procedure Guidance No. 142. London, UK: NICE; November 2005

Blomström-Lundqvist C, Johansson B, et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: The SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). *Eur Heart J*. 2007;28(23):2902-2908.

Neuwirth R, Fiala M, Branny P, et al. Long term effectiveness of surgical cryoablation for chronic atrial fibrillation in patients undergoing surgery for severe mitral valve regurgitation. *Vnitr Lek*. 2007;53(2):151-156.

Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. *Int J Gynaecol Obstet*. 2013;120(3):218-223.

Martin-Hirsch PP, Paraskeva E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. *Cochrane Database Syst Rev*. 2010;(6):CD001318

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v2.2023 Kidney cancer

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v1.2022 Pancreatic adenocarcinoma tumors

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v1.2022 Neuroendocrine tumors.

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v1.2023 Small cell lung cancer.

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v4.2022 Non-small cell lung cancer

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v2.2022 Hepatobiliary cancer

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology v1.2022 Colon cancer

National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology v1.2023 Bone cancers

Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. Mar 2015; 26(3): 312-9

de Baere T, Tselikas L, Woodrum D, et al. Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year. J Thorac Oncol. Oct 2015; 10(10): 1468-74.

Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). J Thorac Oncol. Jul 2020; 15(7): 1200-1209.

Leppelmann KS , Levesque VM, Bunck AC, et al. Outcomes following percutaneous microwave and cryoablation of lung metastases from adenoid cystic carcinoma of the head and neck: A bi-institutional retrospective cohort study. Ann Surg Oncol. 2021;28(11):5829-5839

This policy will be revised as necessary and reviewed no less than annually.

Devised: 08/09/06

Revised: 9/07 (add'l exclusion added); 10/10 (indications added), 10/11(added T stages, and defined renal insufficiency); 10/15 (added indications), 10/16, 9/17 (Added Medicaid Exception); 9/20 (add indications); 9/21 (add nerve pain indication); 9/22 (add lung CA indication)

Reviewed: 9/08, 9/09, 10/12, 10/13, 10/14, 9/18, 9/19

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.